The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarks & Spencer Regulatory News (MKS)

Share Price Information for Marks & Spencer (MKS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 261.50
Bid: 261.60
Ask: 261.80
Change: 0.80 (0.31%)
Spread: 0.20 (0.076%)
Open: 262.20
High: 262.80
Low: 259.10
Prev. Close: 260.70
MKS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Katie Bickerstaffe - Planned Leadership Evolution

7 Mar 2024 08:40

RNS Number : 9852F
Marks and Spencer Group PLC
07 March 2024
 

 

MARKS AND SPENCER GROUP PLC

PLANNED LEADERSHIP EVOLUTION AT M&S

 

Katie Bickerstaffe will retire from M&S after the AGM in July 2024 to pursue her board career.

 

Katie served as a Non-Executive Director and Co-Chief Operating Officer of M&S prior to being appointed Co-CEO, reporting into Chief Executive Officer Stuart Machin, in March 2022. Having helped see through that leadership change, the strengthening of the management team and a marked improvement in the performance of the business, she will move on to take other board roles in line with the original transition plan.

 

"I'm very grateful to Katie for her support in seeing M&S through this important period in the reshaping of the business. We now have a much stronger business, and she will move on with our very best wishes," commented Stuart Machin, CEO.

 

Katie Bickerstaffe said, "I took on the Co-CEO role to support Stuart as he succeeded to Chief Executive Officer and because of my love for the brand and my determination to see the transformation of M&S through to the next stage. We have built a strong team, made great progress, and it is now right that the business and function heads report directly to Stuart. I will leave with great memories and a strong sense of achievement."

 

This announcement has been made in accordance with the requirements of 9.6.11 of the UK Listing Rules.

 

 

ENDS

Notes to Editors

· Katie Bickerstaffe joined M&S as a Non-Executive Director in 2018 and moved into an executive role in 2020, becoming co-Chief Operating Officer alongside Stuart Machin in 2021. In May 2022 Stuart took over as Chief Executive Officer and Katie became co-Chief Executive Officer, reporting into him to oversee some parts of the business. Katie's particular focus has been on Data, Digital and Technology and, as announced on 25 January, Rachel Higham will be joining M&S from WPP in the new financial year to take over this function, reporting to Stuart, and will sit on the Executive Committee.

 

· Katie has always been clear that once this transition was complete, she would want to develop her board career alongside the positions she already holds at Barratt Developments PLC and the England and Wales Cricket Board.

 

The following information is provided pursuant to section 430(2B) of the Companies Act 2006. The following terms have been agreed with Katie Bickerstaffe in connection with her departure and are in line with the Company's Remuneration Policy which was approved by shareholders at the 2023 AGM.

 

Salary, Benefits and Pension 

· Katie will continue to receive her normal remuneration in terms of salary, pension, and company benefits, in accordance with her service agreement, up to and including 10 July 2024. 

· In deciding on her arrangements, the Committee has not wanted to pay excessively in the context of the remainder of her notice period following her departure. To achieve this, Katie will not receive any of her fixed pay elements (including basic salary, pension, and company benefits) from 10 July 2024. 

 

Bonus 

· The Remuneration Committee has determined that, as a good leaver, Katie will be eligible to receive a bonus in respect of the Company's financial year ending 30 March 2024, as she will have worked for the Group throughout this period.

· The amount of any bonus will be subject to the satisfaction of the relevant performance criteria. 

· Katie will not be eligible to receive any bonus in respect of the financial year ending 29 March 2025. 

· All DSBP awards will remain subject to all scheme rules, including malus and clawback provisions.

 

PSP 

· The Remuneration Committee has determined that Katie will be treated as a good leaver in respect of her unvested awards under the Marks and Spencer Performance Share Plan. 

· Her 2021, 2022 and 2023 PSP awards will vest at the normal vesting dates, subject to the relevant plans, achievement of the relevant performance criteria and subject to time pro-ration. 

· All PSP awards will remain subject to all scheme rules, including post-vesting holding periods and malus and clawback provisions.

 

RSP 

· During her time as Chief Strategy and Transformation Director, Katie was granted an award under the Marks and Spencer Restricted Share Plan in line with all other Executive Committee members at the time. 

· The Remuneration Committee has determined that Katie will be treated as a good leaver in respect of her unvested awards under the Marks and Spencer Restricted Share Plan. 

· Her award will vest at the normal vesting date subject to time pro-ration. 

· Her award will remain subject to all scheme rules, including malus and clawback provisions. 

 

Further details of the contractual and leaving provisions for Katie will be summarised in the Directors' Remuneration Report in the 2024 Annual Report & Financial Statements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEAPDXEDNLEEA
Date   Source Headline
2nd Apr 20249:00 amRNSTotal Voting Rights
28th Mar 20245:23 pmRNSHolding(s) in Company
28th Mar 20243:07 pmRNSDirector/PDMR Shareholding
26th Mar 20243:07 pmRNSDirector/PDMR Shareholding
7th Mar 20243:16 pmRNSHolding(s) in Company
7th Mar 20248:40 amRNSKatie Bickerstaffe - Planned Leadership Evolution
4th Mar 20243:11 pmRNSDirector/PDMR Shareholding
1st Mar 20249:00 amRNSTotal Voting Rights
28th Feb 20241:43 pmRNSDirector/PDMR Shareholding
16th Feb 20249:00 amRNSDirector Declaration
1st Feb 20249:00 amRNSTotal Voting Rights
30th Jan 20242:53 pmRNSDirector/PDMR Shareholding
15th Jan 20244:00 pmRNSDirector/PDMR Shareholding
15th Jan 20242:36 pmRNSHolding(s) in Company
11th Jan 20247:00 amRNSChristmas 2023/2024 Trading
10th Jan 20243:28 pmRNSChange To Board Committee Membership
5th Jan 20244:23 pmRNSHolding(s) in Company
2nd Jan 20249:00 amRNSTotal Voting Rights
2nd Jan 20249:00 amRNSBlock listing Interim Review
28th Dec 202311:40 amRNSDirector/PDMR Shareholding
20th Dec 202311:36 amRNSHolding(s) in Company
19th Dec 202310:30 amRNSDirector/PDMR Shareholding
14th Dec 20237:00 amRNSAdditional Listing
12th Dec 20239:13 amRNSDirector/PDMR Shareholding
1st Dec 20239:00 amRNSTotal Voting Rights
28th Nov 20232:55 pmRNSDirector/PDMR Shareholding
9th Nov 202310:29 amRNSDirector/PDMR Shareholding
8th Nov 20237:00 amRNSHalf-year Report
1st Nov 20239:00 amRNSTotal Voting Rights
30th Oct 20235:01 pmRNSDirector/PDMR Shareholding
2nd Oct 20239:00 amRNSTotal Voting Rights
28th Sep 20233:18 pmRNSDirector/PDMR Shareholding
20th Sep 20233:33 pmRNSHolding(s) in Company
20th Sep 20239:00 amRNSDirector/PDMR Shareholding
19th Sep 20239:01 amRNSDirector/PDMR Shareholding
1st Sep 20239:00 amRNSTotal Voting Rights
30th Aug 202310:34 amRNSDirector/PDMR Shareholding
16th Aug 20233:00 pmRNSDirector/PDMR Shareholding
15th Aug 20237:00 amRNSTrading Update and Outlook for the Year
1st Aug 20239:00 amRNSTotal Voting Rights
28th Jul 202311:33 amRNSDirector/PDMR Shareholding
7th Jul 20234:18 pmRNSDirector/PDMR Shareholding
4th Jul 20232:13 pmRNSResult of AGM
3rd Jul 20239:00 amRNSTotal Voting Rights
3rd Jul 20239:00 amRNSBlock listing Interim Review
28th Jun 20232:01 pmRNSDirector/PDMR Shareholding
19th Jun 20234:41 pmRNSDirector/PDMR Shareholding
8th Jun 20235:01 pmRNSHolding(s) in Company
7th Jun 20232:56 pmRNSHolding(s) in Company
6th Jun 202310:00 amRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.